How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia (Q56879722)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

0 references

Angel Paternina-Caicedo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

Carlos A Castañeda-Orjuela

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Martha Velandia-Gonzalez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Fernando De la Hoz-Restrepo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Oscar Gamboa-Garay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

English

0 references

publication date

19 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

402-409

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

Sorivudine: a promising drug for the treatment of varicella-zoster virus infection

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Preventing varicella-zoster disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The burden of varicella complications before the introduction of routine varicella vaccination in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Decline in mortality due to varicella after implementation of varicella vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Varicella vaccine effectiveness in the US vaccination program: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Seroprevalence of varicella zoster and rubella antibodies among rural populations of the Chaco region, south-eastern Bolivia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Susceptibility to varicella-zoster infection in individuals 1 to 29 years of age in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Seroepidemiology of Varicella zoster in Israel prior to large-scale use of varicella vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Hospitalization for primary varicella-zoster virus infection and its complications in patients from Southern Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Chickenpox complications in Saudi Arabia: Is it time for routine varicella vaccination?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Changing varicella epidemiology in active surveillance sites--United States, 1995-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Varicella prevention in the United States: a review of successes and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Modelling the impact of immunization on the epidemiology of varicella zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Cost-effectiveness of a routine varicella vaccination program for US children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Costs And Benefits Of Routine Varicella Vaccination In German Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Childhood vaccination against chickenpox: an analysis of benefits and costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

A cost benefit analysis of routine varicella vaccination in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The cost-effectiveness of varicella vaccine programs for Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Cost–benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The cost-effectiveness of routine childhood varicella vaccination in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Varicella vaccination in Italy : an economic evaluation of different scenarios

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Cost containment analysis of childhood vaccination against varicella in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Economic evaluation of varicella vaccination in Spain: results from a dynamic model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

An economic analysis of the universal varicella vaccination program in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Effectiveness over time of varicella vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The effectiveness of the varicella vaccine in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Varicella outbreaks after vaccine licensure: should they make you chicken?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

The cost-effectiveness of varicella vaccination in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.100

10.1016/J.VACCINE.2012.10.100

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23174195%20AND%20SRC:MED&resulttype=core&format=json